Volume 17, Number 8—August 2011
Letter
Seroepidemiology of Saffold Cardiovirus Type 2
Table
Country | No. samples | Patient age† | Years collected | No. (%) samples |
||||
---|---|---|---|---|---|---|---|---|
SAFV-2 pos‡ | SAFV-3 pos‡ | SAFV pos§ | SAFV-2 pos + SAFV-3 neg | SAFV-2 neg + SAFV-3 pos | ||||
Netherlands | 29 | 9 mo | 2006–2007 | 15 (52) | 4 (14) | 15 (52) | 11 | 0 |
Netherlands | 26 | 24 mo | 2006–2007 | 21 (81) | 20 (77) | 25 (96) | 5 | 4 |
Netherlands | 30 | 18–39 y | 2004 | 30 (100) | 29 (97) | 30 (100) | 1 | 0 |
Finland | 30 | 2–2.5 y | 1997–1998 | 10 (33) | 21 (70) | 24 (80) | 3 | 14 |
Cameroon | 29 | 5–15 y | 1997 | 28 (97) | 28 (97) | 29 (100) | 1 | 1 |
Indonesia | 30 | 4–40 y | 1997–1998 | 30 (100) | 30 (100) | 30 (100) | 0 | 0 |
*SAFV, Saffold virus; pos, positive; neg, negative.
†Samples were collected from patients at this age or within this age range.
‡Titer >15.
§Cumulative positive for antibodies against SAFV-2 and/or SAFV-3.
Page created: August 15, 2011
Page updated: August 15, 2011
Page reviewed: August 15, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.